Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes.
Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7
Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their early introduction can provide better outcomes. To offer those living with Crohn’s disease or ulcerative colitis the best treatment, we must increase patient access to biological treatments at the most optimal time. The introduction of biosimilars can facilitate this.”
Speaking at ISPOR, Professor Gulácsi, Head of Department of Health Economics, Corvinus University of Budapest HTA Consulting, Hungary, concluded that, “According to the budget impact study of CT-P13, if budget savings were spent on reimbursement of additional biosimilar infliximab treatment, approximately 10-15% more patients could be treated in high and middle-income countries.”
Mr HoUng Kim, Head of Strategy and Operations at Celltrion Healthcare, addressed the issue of limited early access to biological treatment at the congress in a statement:
“Patients should have the option of receiving the best possible treatment as early as possible. As a company we are strongly committed to delivering innovative and affordable treatments for people living with chronic conditions across the world by providing high quality, cost effective biosimilars. Now is the time for payers, physicians and health economists to re-evaluate the cost effectiveness of biological treatment in light of the introduction of biosimilars and to address inconsistencies in patient access.”
Mr HoUng Kim went on to explain that a lack of understanding of biosimilars in some healthcare systems, doctors’ conservative prescribing behaviours and the high development and manufacturing costs associated with biologics as current obstacles when seeking to treat patients early with biological therapies..
The Celltrion Healthcare presentation as ISPOR also included perspectives from leading physicians:
- Professor Jørgen Jahnsen, Akershus University Hospital, Norway shared his perspective on the early introduction of biologics in inflammatory bowel disease, showing that the early introduction of anti-TNF alpha agents brought the most clinical benefit to patients
- Professor László Gulácsi, Corvinus University, Hungary provided an overview on how reducing healthcare costs can result in improved access to treatments
- Dr Edmund Pezalla, Former Vice President, Aetna, U.S. provided an analysis of the uptake of biosimilars in United States healthcare environment.
Notes to editors:
Dr Edmund Pezalla, Former Vice President, Aetna, U.S., said: “President Trump’s recent blueprint marks as an important step toward lowering the prices of prescription drugs in the United States. This decision is promising to expand access to biosimilars and raising awareness about the potential of biosimilars to lower drug costs. As this appears to be a major endorsement of price transparency, and also allow Medicare Part D plan sponsors to promote lower cost generics and biosimilars, there’s no doubt that the tide is finally turning for patient access to very expensive treatments for complex conditions at lower costs.”
About inflammatory bowel disease
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.8 They affect an estimated 2.5-3 million people in Europe;9 CD affects about three people per 1,000 and UC about 5 people per 1,000.8
IBDs account for substantial costs to the healthcare system and society; the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.9
About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in Europe in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 87 countries (as of May 2018) including the US, Canada, Japan and throughout Europe.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/
1 G D'Haens, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 660–67.
2 Colombel JF, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N EnglJ Med. 2010 Apr 15;362(15):1383-95.
3 Colombel JF, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 Oct 30. pii: S0140-6736(17)32641-7.
4 St Clair EW, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. ArthritisRheum.2004 Nov;50(11):3432-43.
5 Baranauskaite A, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-548
6 Emery P, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanerceptin active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375-82.
7 IMS Health. The Impact of Biosimilar Competition. June 2016. Available at: file:///C:/Users/gfeatherston/Downloads/IMS%20Impact%20of%20Biosimilar%20Competition%202016.pdf
8 Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1)46–54.
9 Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis. 2013; 7,322-337.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Exterior Plus, a Portfolio Company of H.I.G. Capital, Acquires Impactmedia23.10.2018 16:03 | Tiedote
Exterior Plus, the out-of-home advertising platform of H.I.G. Capital, announces the acquisition of Impactmedia (the “Company”), a leading shopping mall advertising company, with over 630 million viewers in high-traffic premium locations throughout Spain. This is a major step forward in Exterior Plus’s consolidation strategy, as it aims to become the Spanish leader in out-of-home advertising with a unique, diversified and highly-competitive product portfolio, reaching very diverse audiences at a national level. Impactmedia is an experienced leader in shopping mall advertising, offering digital advertising as well as special marketing actions. The Company operates in over 90 shopping centers where it has more than 1,200 digital displays. The acquisition allows Exterior Plus to gain a strong presence near points of sale, a key value driver for advertisers. H.I.G. Capital acquired and established the Exterior Plus group in December 2015. The group currently markets more than 25,000 advert
Visa Brings a Simpler, Safer Experience to Digital Payments23.10.2018 16:00 | Tiedote
Visa (NYSE: V) today announced a continued commitment to reducing friction and improving security in digital commerce by reiterating support of the draft EMV® Secure Remote Commerce (SRC) Specification. The draft EMV SRC Specification provides a foundation for digital transactions that gives consumers, merchants and issuers a single digital point-of-sale, resulting in a consistent, convenient and secure way to pay. EMVCo has spent the last year gathering feedback from across the payment ecosystem on the specification. Visa now encourages merchants, issuers, acquirer gateways and other interested participants to provide feedback and comment during a 45-day public comment window. Once complete, EMVCo will publish the final specification. Shoppers are increasingly migrating to websites, mobile phones and voice-activated devices, but their buying experiences are full of friction because they are required to manually enter payment details. With SRC, consumers’ digital buying experiences wil
Active-Semi’s New PMICs Reduce Size and Increase Power Density with Leading Field Programable Technology23.10.2018 16:00 | Tiedote
The ACT88325 and ACT88326 PMICs are integrated field programmable ActivePMU™ power management units, also referred to as PMICs (Power Management ICs). The products are highly flexible with non-volatile memory and come pre-programmed and can be field programmed via I²C or via GPIOs for multiple applications. The ACT88325 powers up based on the preconfigured startup sequence as soon as power is applied to the input pin, whereas ACT88326 implements a Push Button Startup that relies on a customer’s interaction with, for example, a portable application like an Action Camera, Video Doorbell, Body Camera or other handheld applications. “Low external component count, extremely small WLCSP package and high configurability significantly speeds time to market and reduces PCB size and BOM cost,” says David Briggs, VP and General Manager of Power Solutions at Active-Semi. “The ACT88325 and ACT88326 are a great addition to our lineup and are specifically designed for the highest power density in SSD
New Nordson EFD Fluid Dispensing Video Gallery is Now Live23.10.2018 15:23 | Tiedote
Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, announces the launch of a new online video portal, which is now live and can be viewed at videos.nordsonefd.com. The portal can also be accessed through Nordson EFD’s existing Video Gallery web page at nordsonefd.com/videos. EFD strives to satisfy its customer base and wanted to create a more efficient and user-friendly video interface. The video gallery is organized with all videos on one main page so users do not have to search through different web pages to find what they need. “Generating product and application knowledge through video is important to EFD and users should receive the best experience possible,” said Rhonda Mitchell, Global Marketing Communications Manager at Nordson EFD. EFD’s new video gallery provides more than 200 videos in English and nine other languages. The gallery is organized by categories that are divided into subcategories, which makes loca
PotNetwork Holdings, Inc. Reports $18.1 Million in Sales Surpassing Entire Revenue Generated in 201723.10.2018 15:00 | Tiedote
PotNetwork Holdings, Inc. (OTC Pink: POTN ) today announced sales of $18.1 Million for the first 9 months of the year, realizing an $8.6 Million increase in year over year sales. This follows the Company’s recent announcement of its record third quarter revenues of $6.1 Million. Driven by the growth of its wholly-owned subsidiary, Diamond CBD, Inc., PotNetwork Holdings, Inc. has taken root as an industry leader in the growing market for premium hemp extracts. PotNetwork Holdings is expanding its research and development, multinational marketing and international distribution of a broad range of hemp-derived cannabinoids and other natural hemp derivatives. PotNetwork Holdings also reported that sales of Diamond CBD Products are coming 60% from its wholesale distribution network and 40% from online sales including from www.diamondcbd.com. “I am extremely pleased with our year-over-year growth,” said Kevin Hagen, president of Diamond CBD. “We provide customers with a high-quality product
Safe Group sells its Safe Cronite business to focus on Safe Metal and Safe Demo23.10.2018 15:00 | Tiedote
On October 18 th , Safe Group sold its Safe Cronite business area, including the Swiss holding company Cronite SA and all its manufacturing plants and sales offices, to new shareholders brought together by Pierre Wittmann and managers in partnership with investment funds driven by Ciclad. The Safe Cronite business area, which has been gradually incorporated into the Safe Group since 1983, is a world leader in the design and production of refractory steel tools and components resistant to high temperatures and thermal shocks. Safe Cronite achieved a consolidated turnover of EUR 74 million in 2017 and employs around 800 people. It operates 7 plants in France, England, Germany, China, India, Mexico, and has a R & D and Design Center in the Czech Republic. Its sales offices in the United States, Japan, South Korea and Sweden propel a global coverage of 2,000 customers in the automotive, aerospace, incineration and steel markets. This divestment is part of the implementation of the new Safe
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme